vs
OPENLANE, Inc.（OPLN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是OPENLANE, Inc.的1.6倍（$772.1M vs $494.3M），Revvity净利率更高（12.7% vs 12.0%，领先0.7%），OPENLANE, Inc.同比增速更快（8.6% vs 5.9%），Revvity自由现金流更多（$161.8M vs $110.8M），过去两年Revvity的营收复合增速更高（9.0% vs 7.2%）
OPENLANE Inc.是全球领先的数字化汽车批发交易平台运营商，连接汽车经销商、车队运营商、金融机构等卖家与专业买家，提供二手车、租赁到期车辆等的透明高效交易服务，业务覆盖北美、欧洲等全球主要市场。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
OPLN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$494.3M
营收增速更快
OPLN
高出2.8%
5.9%
净利率更高
RVTY
高出0.7%
12.0%
自由现金流更多
RVTY
多$51.0M
$110.8M
两年增速更快
RVTY
近两年复合增速
7.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $494.3M | $772.1M |
| 净利润 | $59.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 8.6% | 14.5% |
| 净利率 | 12.0% | 12.7% |
| 营收同比 | 8.6% | 5.9% |
| 净利润同比 | 13.8% | 3.9% |
| 每股收益（稀释后） | $-1.54 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPLNRVTY
| Q4 25 | $494.3M | $772.1M | ||
| Q3 25 | $498.4M | $698.9M | ||
| Q2 25 | $481.7M | $720.3M | ||
| Q1 25 | $460.1M | $664.8M | ||
| Q4 24 | $455.0M | $729.4M | ||
| Q3 24 | $459.8M | $684.0M | ||
| Q2 24 | $443.8M | $691.7M | ||
| Q1 24 | $429.9M | $649.9M |
净利润OPLNRVTY
| Q4 25 | $59.5M | $98.4M | ||
| Q3 25 | $47.9M | $46.7M | ||
| Q2 25 | $33.4M | $53.9M | ||
| Q1 25 | $36.9M | $42.2M | ||
| Q4 24 | $52.3M | $94.6M | ||
| Q3 24 | $28.4M | $94.4M | ||
| Q2 24 | $10.7M | $55.4M | ||
| Q1 24 | $18.5M | $26.0M |
毛利率OPLNRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率OPLNRVTY
| Q4 25 | 8.6% | 14.5% | ||
| Q3 25 | 11.0% | 11.7% | ||
| Q2 25 | 9.8% | 12.6% | ||
| Q1 25 | 11.2% | 10.9% | ||
| Q4 24 | 17.4% | 16.3% | ||
| Q3 24 | 9.2% | 14.3% | ||
| Q2 24 | 5.4% | 12.4% | ||
| Q1 24 | 8.6% | 6.8% |
净利率OPLNRVTY
| Q4 25 | 12.0% | 12.7% | ||
| Q3 25 | 9.6% | 6.7% | ||
| Q2 25 | 6.9% | 7.5% | ||
| Q1 25 | 8.0% | 6.4% | ||
| Q4 24 | 11.5% | 13.0% | ||
| Q3 24 | 6.2% | 13.8% | ||
| Q2 24 | 2.4% | 8.0% | ||
| Q1 24 | 4.3% | 4.0% |
每股收益（稀释后）OPLNRVTY
| Q4 25 | $-1.54 | $0.86 | ||
| Q3 25 | $0.25 | $0.40 | ||
| Q2 25 | $0.15 | $0.46 | ||
| Q1 25 | $0.18 | $0.35 | ||
| Q4 24 | $0.28 | $0.77 | ||
| Q3 24 | $0.12 | $0.77 | ||
| Q2 24 | $0.00 | $0.45 | ||
| Q1 24 | $0.05 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $141.5M | $919.9M |
| 总债务越低越好 | $550.0M | — |
| 股东权益账面价值 | $1.2B | $7.3B |
| 总资产 | $4.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资OPLNRVTY
| Q4 25 | $141.5M | $919.9M | ||
| Q3 25 | $119.3M | $931.4M | ||
| Q2 25 | $119.1M | $991.8M | ||
| Q1 25 | $220.5M | $1.1B | ||
| Q4 24 | $143.0M | $1.2B | ||
| Q3 24 | $132.1M | $1.2B | ||
| Q2 24 | $60.9M | $2.0B | ||
| Q1 24 | $105.2M | $1.7B |
总债务OPLNRVTY
| Q4 25 | $550.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $230.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益OPLNRVTY
| Q4 25 | $1.2B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.3B | $7.9B | ||
| Q1 24 | $1.3B | $7.8B |
总资产OPLNRVTY
| Q4 25 | $4.7B | $12.2B | ||
| Q3 25 | $4.8B | $12.1B | ||
| Q2 25 | $4.6B | $12.4B | ||
| Q1 25 | $4.8B | $12.4B | ||
| Q4 24 | $4.6B | $12.4B | ||
| Q3 24 | $4.6B | $12.8B | ||
| Q2 24 | $4.6B | $13.4B | ||
| Q1 24 | $4.8B | $13.4B |
负债/权益比OPLNRVTY
| Q4 25 | 0.44× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.17× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $110.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 22.4% | 21.0% |
| 资本支出强度资本支出/营收 | 3.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.11× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $336.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流OPLNRVTY
| Q4 25 | $125.5M | $182.0M | ||
| Q3 25 | $72.2M | $138.5M | ||
| Q2 25 | $71.6M | $134.3M | ||
| Q1 25 | $122.6M | $128.2M | ||
| Q4 24 | $32.7M | $174.2M | ||
| Q3 24 | $122.4M | $147.9M | ||
| Q2 24 | $37.5M | $158.6M | ||
| Q1 24 | $100.2M | $147.6M |
自由现金流OPLNRVTY
| Q4 25 | $110.8M | $161.8M | ||
| Q3 25 | $57.6M | $120.0M | ||
| Q2 25 | $57.4M | $115.5M | ||
| Q1 25 | $110.7M | $112.2M | ||
| Q4 24 | $18.7M | $149.8M | ||
| Q3 24 | $109.3M | $125.6M | ||
| Q2 24 | $24.5M | $136.6M | ||
| Q1 24 | $87.3M | $129.7M |
自由现金流率OPLNRVTY
| Q4 25 | 22.4% | 21.0% | ||
| Q3 25 | 11.6% | 17.2% | ||
| Q2 25 | 11.9% | 16.0% | ||
| Q1 25 | 24.1% | 16.9% | ||
| Q4 24 | 4.1% | 20.5% | ||
| Q3 24 | 23.8% | 18.4% | ||
| Q2 24 | 5.5% | 19.7% | ||
| Q1 24 | 20.3% | 20.0% |
资本支出强度OPLNRVTY
| Q4 25 | 3.0% | 2.6% | ||
| Q3 25 | 2.9% | 2.6% | ||
| Q2 25 | 2.9% | 2.6% | ||
| Q1 25 | 2.6% | 2.4% | ||
| Q4 24 | 3.1% | 3.4% | ||
| Q3 24 | 2.8% | 3.3% | ||
| Q2 24 | 2.9% | 3.2% | ||
| Q1 24 | 3.0% | 2.7% |
现金转化率OPLNRVTY
| Q4 25 | 2.11× | 1.85× | ||
| Q3 25 | 1.51× | 2.97× | ||
| Q2 25 | 2.14× | 2.49× | ||
| Q1 25 | 3.32× | 3.03× | ||
| Q4 24 | 0.63× | 1.84× | ||
| Q3 24 | 4.31× | 1.57× | ||
| Q2 24 | 3.50× | 2.87× | ||
| Q1 24 | 5.42× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPLN
| Marketplace | $384.7M | 78% |
| Finance | $109.6M | 22% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
